Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NowFoods glucosamine, chondroitin subpotency error

This article was originally published in The Tan Sheet

Executive Summary

Supplement manufacturer will clarify labeling after confusion regarding potency of Now Double Strength Glucosamine & Chondroitin and Now Chondroitin Sulfate caused Consumer Reports to incorrectly list supplements as subpotent in its January issue, company says (1"The Tan Sheet" Dec. 17, 2001, p. 18). NowFoods President/CEO Elwood Richard sent Dec. 14 letter to CR detailing the error, and in early December CR's analytical laboratory director confirmed firm's assertion, NowFoods says. Company's Web site currently displays Jan. 10 letter to customers explaining error's resolution...

Supplement manufacturer will clarify labeling after confusion regarding potency of Now Double Strength Glucosamine & Chondroitin and Now Chondroitin Sulfate caused Consumer Reports to incorrectly list supplements as subpotent in its January issue, company says (1 (Also see "Dietary Supplement Tax Reform Bill Complements CAM Commission Efforts" - Pink Sheet, 17 Dec, 2001.), p. 18). NowFoods President/CEO Elwood Richard sent Dec. 14 letter to CR detailing the error, and in early December CR's analytical laboratory director confirmed firm's assertion, NowFoods says. Company's Web site currently displays Jan. 10 letter to customers explaining error's resolution....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel